No AI deployment in a regulated industry is risk-free, and pharma leaders deserve straight answers about what can go wrong. This FAQ addresses the genuine challenges and concerns Indian pharma companies raise before and during AI adoption, without glossing over the difficult parts.
1. What is the biggest challenge pharma companies face when adopting AI?
The biggest challenge is usually organizational adoption rather than the technology itself — getting field staff, pharmacists, or compliance reviewers to trust and consistently use a new AI-driven workflow. Even a highly accurate AI system delivers no value if MRs quietly continue their old manual reporting habits alongside it, or if pharmacists ignore AI-suggested substitutions out of habit. Overcoming this requires clear communication about what the AI is for, visible leadership support, and early wins that demonstrate the tool genuinely reduces work rather than adding a new task on top of existing ones.
2. Can AI make mistakes in a pharma context, and how serious are the consequences?
Yes, AI can make mistakes such as misclassifying a document field, mishearing a spoken drug name, or suggesting an incorrect generic substitute, and the consequences range from minor inefficiency to genuine patient safety concern depending on where the error occurs. This is why pharma AI deployments should always include human review checkpoints for anything touching clinical decisions, regulatory filings, or direct patient guidance on medication. Companies that treat AI outputs as a first draft requiring validation, rather than a final answer, manage this risk effectively, while those that remove human oversight too early expose themselves to real risk.
3. Is there a risk that patients or doctors will not trust AI-driven communication?
Yes, some patients and doctors are skeptical of AI-driven calls or messages, particularly around sensitive topics like medication side effects or when they cannot immediately tell whether they are speaking with a human or an automated system. Transparency helps significantly — clearly identifying when a call is AI-assisted, and making it easy to reach a human when the caller wants one, reduces distrust considerably. Trust also builds over time as patients and doctors experience the AI system being accurate and genuinely useful rather than a frustrating obstacle, similar to how attitudes toward automated banking and telecom systems have shifted as those systems improved.
4. What are the risks of AI providing incorrect medical or drug information?
The risk of AI providing incorrect medical or drug information is serious, which is why pharma AI systems should be strictly scoped to approved product information and configured to escalate any query beyond that scope to a qualified pharmacist or physician rather than attempting to answer independently. An AI system that improvises an answer about dosage, interactions, or side effects outside its approved knowledge base creates both a patient safety risk and a regulatory compliance risk under CDSCO promotion and labeling rules. Rigorous content boundaries and regular audits of the AI's actual responses in production are essential controls, not optional extras.
5. How difficult is it to get AI systems to work well across India's many regional languages and dialects?
It is a genuine challenge — Indian languages vary significantly in dialect and colloquial usage across states, and a system trained primarily on formal or standard language forms can struggle with how patients or doctors actually speak in everyday conversation. Pharma companies with patient populations across rural and semi-urban India, where regional dialects are strongest, need to specifically validate AI language performance in those areas rather than assuming a system that works well in a metro pilot will perform equally well nationwide. This is one of the most commonly underestimated challenges in scaling pharma AI beyond an initial city-based pilot.
6. Will AI adoption lead to job losses for MRs, pharmacists, or compliance staff?
AI adoption in pharma is generally reshaping roles rather than eliminating them outright — MRs shift from administrative reporting toward more selling and relationship time, and compliance reviewers shift from manual data checking toward judgment-based review of AI-flagged exceptions. That said, it is a legitimate concern that staff raise, and companies that are not transparent about this shift risk resistance and quiet sabotage of the new tools. Being upfront that AI is meant to reduce administrative burden and improve productivity, backed by concrete examples of how existing staff's roles are evolving rather than disappearing, addresses this concern more effectively than avoiding the conversation.
7. What happens if the AI system goes down or gives an unreliable answer during a critical moment?
Any pharma AI deployment should have a clear fallback path — human backup staff, a manual process, or at minimum a way to flag and escalate the interaction — for moments when the system is down or produces a response it is not confident about. This is especially important for time-sensitive scenarios like drug shortage communication or adverse event intake, where a delay or wrong answer has real consequences. Companies should ask vendors directly about system uptime guarantees, fallback mechanisms, and how confidence thresholds are set so uncertain cases are routed to a human rather than answered incorrectly.
8. Is data quality really as big a problem as vendors claim when implementing pharma AI?
Yes, data quality is consistently one of the most significant practical obstacles, and it is not vendor exaggeration — many pharma companies discover during implementation that their CRM records, product master data, or historical documents are inconsistently formatted across regions or business units. An AI system trained or configured on messy underlying data will produce unreliable outputs regardless of how sophisticated the AI model itself is. Budgeting real time for a data quality assessment before implementation, rather than treating it as a minor preliminary step, prevents a significant source of delay and disappointment later in the project.
9. How do pharma companies handle the concern that AI decisions can be hard to explain during an audit?
Pharma companies address this by choosing AI systems that log clear reasoning or source data behind each output and by keeping human sign-off on any decision that ultimately matters for regulatory or patient safety purposes. Auditors and regulators are generally comfortable with AI as a supporting tool as long as the company can show how a decision was reached and that a qualified human reviewed anything consequential. The concern becomes serious only when a company cannot reconstruct why the AI produced a given output, which is why audit logging should be a non-negotiable requirement when selecting an AI vendor for any regulated workflow.
10. What should a pharma company do if an AI pilot underperforms or fails to gain adoption?
A pharma company should treat an underperforming pilot as diagnostic information rather than a reason to abandon AI altogether — the specific cause, whether it is poor data quality, weak change management, or a mismatched use case, usually points to a fixable issue rather than a fundamental flaw in the technology. It is worth conducting a structured post-pilot review involving actual users to understand exactly where adoption broke down, since the root cause is often organizational rather than technical. Many successful pharma AI deployments follow an earlier pilot that did not go as planned, refined based on specific, honest feedback rather than a generic retry of the same approach.
Related Reading
Related reading
Talk to YuVerse
Talk through your specific concerns with a team that has deployed AI in regulated industries: talk to us.